A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)

NCT00718549 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

128

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphocytic Leukemia, Chronic

Interventions

DRUG: Cladribine
DRUG: Cyclophosphamide
DRUG: Rituximab

Sponsor

Hoffmann-La Roche